UCB SA (OTCMKTS:UCBJY – Get Free Report) shares hit a new 52-week high on Wednesday . The stock traded as high as $100.43 and last traded at $100.18, with a volume of 7440 shares changing hands. The stock had previously closed at $98.57.
UCB Stock Down 0.4 %
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average is $96.66 and its two-hundred day moving average is $90.00.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- How Investors Can Find the Best Cheap Dividend Stocks
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is a Low P/E Ratio and What Does it Tell Investors?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- How Technical Indicators Can Help You Find Oversold Stocks
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
